Genmab's drug candidate given Fast Track Status  

The US Food and Drug Administration (FDA) has given Fast Track Status to Genmab's HuMax-CD4 for the treatment of lymphoma

Genmab has announced that its drug candidate HuMax-CD4 for the treatment of lymphoma has been given Fast Track Status by the US Food and Drug Administration (FDA). Fast Track Status means that FDA accelerates the processing of a drug application when a drug is for the treatment of a serious and life threatening condition and shows the potential to meet needs for treatment which up to now have been unmet.


HuMax-CD4 is currently being tested in two phase II trials for the treatment of cutaneous T-cell lymphoma (CTCL), one in early stage patients and the other for patients with advanced disease. Lisa Drakeman, CEO of Genmab says that the Fast Track Status confirms a major unmet medical need for treatment of CTCL patients.


Genmab is headquartered in Copenhagen and has operations in Utrecht, Holland and Princeton, New Jersey. Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases such as cancer and rheumatoid arthritis. The news is reported by BiotechDenmark online and on Genmab's website.


Link > Genmab 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×